PTGIS, PTGES, and PTGER4 up-regulation in the group of responders with HER2-positive breast cancer, known by its aggressive behavior [132,133], is associated with complete tumor response to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC). Here, ERBB2 is linked to breast carcinoma.